Comments on: AstraZeneca sells rights to Grunenthal https://ukinvestor.foxrobinson.com/astrazeneca-sells-rights-to-grunenthal/ Thu, 21 Feb 2019 15:34:27 +0000 hourly 1 https://wordpress.org/?v=6.6.2 By: AstraZeneca meets guidance as new medicines lead strong performance - UK Investor Magazine https://ukinvestor.foxrobinson.com/astrazeneca-sells-rights-to-grunenthal/#comment-9630 Thu, 21 Feb 2019 15:34:27 +0000 https://ukinvestor.foxrobinson.com/?p=15794#comment-9630 […] rights to its respiratory tract infection treatment to the Swedish company Sobi. Additionally, it sold its European rights to an acid-reflux medicine to […]

]]> By: AstraZeneca cancer medicine fails to meet main objective - UK Investor Magazine https://ukinvestor.foxrobinson.com/astrazeneca-sells-rights-to-grunenthal/#comment-8848 Fri, 16 Nov 2018 12:48:27 +0000 https://ukinvestor.foxrobinson.com/?p=15794#comment-8848 […] its US rights to its respiratory tract infection treatment to a Swedish company. Moreover, it also sold the rights to its acid-reflux medicine Grunenthal at the end of last month. Furthermore, it recently published its third quarter earnings and […]

]]> By: AstraZeneca sells US rights to Sobi - UK Investor Magazine https://ukinvestor.foxrobinson.com/astrazeneca-sells-rights-to-grunenthal/#comment-8819 Tue, 13 Nov 2018 08:31:50 +0000 https://ukinvestor.foxrobinson.com/?p=15794#comment-8819 […] sold rights to. At the end of October, the biopharmaceutical company also sold rights to its acid-reflux medicine to Grunenthal. Furthermore, it recently published its third quarter earnings and outlined a contingency plan for […]

]]> By: AstraZeneca earnings drop, Brexit plans outlined - UK Investor Magazine https://ukinvestor.foxrobinson.com/astrazeneca-sells-rights-to-grunenthal/#comment-8797 Thu, 08 Nov 2018 09:42:43 +0000 https://ukinvestor.foxrobinson.com/?p=15794#comment-8797 […] the beginning of October, AstraZeneca sold rights to the German company Grunenthal for an acid-reflux […]

]]>